Cardiff Oncology, Inc.

CRDF · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
518
SEC Filings

Business Summary

We are a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations of onvansertib, our oral and highly selective PLK1 inhibitor, and standard-of-care ("SoC") therapeutics. We are focusing our clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well ...

Next Earnings

Q2 FY2026 — expected 2026-07-18

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionCRDFdiscussed_in_filing Cybersecurity
topic_mentionCRDFdiscussed_in_filing Cybersecurity
topic_mentionCRDFdiscussed_in_filing Healthcare & Bio
topic_mentionCRDFdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-242025-12-310001193125-26-067464EDGAR49K words
2025-02-272024-12-310000950170-25-028992EDGAR—
2024-02-292023-12-310001628280-24-007948EDGAR—
2023-03-022022-12-310001628280-23-006037EDGAR—
2022-02-242021-12-310001628280-22-003808EDGAR—
2021-02-252020-12-310001628280-21-003277EDGAR—
2020-02-272019-12-310001628280-20-002424EDGAR—
2019-03-062018-12-310001628280-19-002546EDGAR—
2018-02-262017-12-310001628280-18-002226EDGAR—
2017-03-152016-12-310001628280-17-002601EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001193125-25-269424EDGAR14K words
2025-07-292025-06-300000950170-25-099610EDGAR—
2025-05-082025-03-310000950170-25-066886EDGAR—
2024-11-072024-09-300000950170-24-123242EDGAR—
2024-08-082024-06-300001628280-24-036098EDGAR—
2024-05-022024-03-310001628280-24-019974EDGAR—
2023-11-022023-09-300001628280-23-036375EDGAR—
2023-08-092023-06-300001628280-23-028549EDGAR—
2023-05-042023-03-310001628280-23-015692EDGAR—
2022-11-032022-09-300001628280-22-028164EDGAR—
2022-08-042022-06-300001628280-22-021044EDGAR—
2022-05-052022-03-310001628280-22-012614EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-020001193125-26-140152EDGAR1K words
2026-02-250001193125-26-068668EDGAR—
2026-02-240001193125-26-067476EDGAR—
2026-01-270001193125-26-024375EDGAR—
2025-11-060001193125-25-269492EDGAR—
2025-07-290000950170-25-099631EDGAR—
2025-06-260001641172-25-016659EDGAR—
2025-06-170000950170-25-087369EDGAR—
2025-05-080000950170-25-066947EDGAR—
2025-02-270000950170-25-029065EDGAR—

518 total filings indexed. 486 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001213037
TickerCRDF
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 2c3279af62455c7ca30b84930e83b3c553855e8fa96a237c4fe96ab880592cf2
parent: 51c8dce8cc989f9d3c8d0d16a98c9776aa2c4fbb8674263847fd13baedd657dc
content hash: 776843e5deed4a44b3c63274e7ea2916a5b5158f48e99031a6758ae35ecd31af
signed: 2026-04-13T04:44:29.062Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf